Analyst Expectations for Adaptimmune Therapeutics's Future
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 5 analysts have published their opinion on Adaptimmune Therapeutics (NASDAQ:ADAP) stock, with 4 giving bullish ratings and 1 somewhat bearish. The average price target is $8.2, a significant increase from the previous average of $2.00, implying a potential upside for the stock.
August 10, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts are largely bullish on Adaptimmune Therapeutics, with a significantly increased average price target, suggesting potential upside.
The majority of analysts have given bullish ratings for ADAP, and the average price target has increased significantly over the past 3 months. This suggests a positive outlook for the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100